Collegium Pharmaceutical

Collegium Pharmaceutical products

H

• HLD200 (evening-dosed methylphenidate ER capsules)

  • Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in children (under development in clinical trials)

N

• Nucynta® — tapentadol (IR)

  • Indication: management of acute pain severe enough to require an opioid when alternatives are inadequate

• Nucynta® ER — tapentadol (extended-release)

  • Indication: management of severe chronic pain in patients requiring around-the-clock opioid therapy for whom alternative treatments are inadequate

• Naldemedine (Symproic®)

  • Indication: opioid-induced constipation (OIC) in adults with chronic non-cancer pain

X

• Xtampza® ER — oxycodone extended-release

  • Indication: severe chronic pain requiring long-term, around-the-clock opioid treatment, with an abuse-deterrent formulation

J

• Jornay® PM — methylphenidate extended-release capsules

• Indication: ADHD in patients aged 6 and older; designed for evening dosing to provide therapeutic effect the next morning